Specify a stock or a cryptocurrency in the search bar to get a summary
Chemomab Therapeutics Ltd DRC
CMMBChemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Address: Building 7, Tel Aviv, Israel, 6158002
Analytics
WallStreet Target Price
8.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CMMB
Dividend Analytics CMMB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CMMB
Stock Valuation CMMB
Financials CMMB
Results | 2019 | Dynamics |